0001104659-26-060297
SEC filingQ1 revenue grew 21.5% to $16.0M driven by Emrosi ramp-up, narrowing operating loss 55.1% to -$1.5M due to reduced launch costs, while cash flow turned positive at $2.9M from smaller net loss and working capital improvements.
Journey Medical Corporation reported Q1 2026 results reflecting revenue acceleration and loss narrowing amid strategic cost management. Revenue rose 21.5% year-over-year to $16.0 million from $13.1 million, supported by the ongoing ramp-up of Emrosi following its launch. This growth dynamic underscores the contribution of new product momentum to top-line expansion in a competitive dermatology market.
Gross profit reached $9.7 million, yielding a 61.0% margin, which reflects effective pricing and mix amid scale benefits. However, operating income remained negative at -$1.5 million, an improvement of 55.1% from the prior year's -$3.3 million. The primary driver was a decrease in selling, general, and administrative expenses, primarily due to a reduction in Emrosi launch costs from the prior year quarter. This cost discipline demonstrates management's focus on optimizing spend post-launch to support path to profitability, even as competitive pressures persist on legacy lines.
Net income narrowed 45.2% to -$2.2 million from -$4.1 million, with diluted EPS improving 55.6% to -$0.08 from -$0.18. These enhancements stem from the reduced operating loss, highlighting progress in core operations. Operating margin stood at -9.3%, still pressured but directionally better, as revenue growth outpaced expense reductions.
A key inflection occurred in cash flow, with net cash provided by operating activities flipping to $2.9 million from a -$2.8 million use of cash in the prior year quarter. This positive shift was driven primarily by the decrease in net loss period-to-period as well as changes in net working capital, primarily related to net collections of accounts receivable. The improvement signals growing operational maturity, converting accounting profits toward cash generation and reducing reliance on external funding.